IMETELSTAT SODIUM - Generic Drug Details

What are the generic drug sources for imetelstat sodium and what is the scope of freedom to operate?

Imetelstat sodium is the generic ingredient in one branded drug marketed by Geron and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Imetelstat sodium has one hundred and seventy-nine patent family members in thirty-eight countries.

One supplier is listed for this compound.

Summary for IMETELSTAT SODIUM

International Patents:	179
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	7
Patent Applications:	80
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IMETELSTAT SODIUM
What excipients (inactive ingredients) are in IMETELSTAT SODIUM?	IMETELSTAT SODIUM excipients list
DailyMed Link:	IMETELSTAT SODIUM at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IMETELSTAT SODIUM

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH LOW - TO INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA REQUIRING 4 OR MORE RED BLOOD CELL UNITS OVER 8 WEEKS WHO HAVE NOT RESPONDED TO OR HAVE LOST RESPONSE TO OR ARE INELIGIBLE FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESA)

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IMETELSTAT SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Children's Oncology Group	Phase 2
National Cancer Institute (NCI)	Phase 2
Pediatric Brain Tumor Consortium	Phase 2

See all IMETELSTAT SODIUM clinical trials

Pharmacology for IMETELSTAT SODIUM

Drug Class	Oligonucleotide Telomerase Inhibitor
Mechanism of Action	Oligonucleotide Telomerase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for IMETELSTAT SODIUM

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for IMETELSTAT SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-002	Jun 6, 2024		RX	Yes	Yes
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-001	Jun 6, 2024		RX	Yes	Yes
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-002	Jun 6, 2024		RX	Yes	Yes			Y	Y
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-001	Jun 6, 2024		RX	Yes	Yes
Geron	RYTELO	imetelstat sodium	POWDER;INTRAVENOUS	217779-001	Jun 6, 2024		RX	Yes	Yes

International Patents for IMETELSTAT SODIUM

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3456333
South Africa	202108991	USE OF TELOMERASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS AND MYELOPROLIFERATIVE NEOPLASMS
European Patent Office	3658156
Japan	2020528915
South Korea	20250151565

Supplementary Protection Certificates for IMETELSTAT SODIUM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3456333	LUC50005	Luxembourg		PRODUCT NAME: IMETELSTAT, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/24/1894 20250311
3456333	122025000019	Germany		PRODUCT NAME: IMETELSTAT, ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1894 20250307
3456333	C20250019	Finland
3456333	CR 2025 00016	Denmark		PRODUCT NAME: IMETELSTAT, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1894 20250311
3456333	PA2025517	Lithuania		PRODUCT NAME: IMETELSTATAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/24/1894 20250307

Imetelstat Sodium: Market and Financial Trajectory Analysis

Last updated: February 12, 2026

Market Overview and Status

Imetelstat sodium (GRN163L) is a telomerase inhibitor under development by Geron Corporation. It targets telomerase activity in hematologic malignancies, primarily myelofibrosis and myelodysplastic syndromes (MDS). The drug has completed phases of clinical development but lacks FDA approval for commercial sale as of the latest data.

Current Development Phase and Regulatory Status

• Phase 2/3 trials for myelofibrosis and MDS are ongoing or pending completion.
• No FDA or EMA approval has been granted; thus, the drug remains in late-stage clinical development, with potential market entry years away contingent on positive outcomes.

Market Potential and Size

The pharmaceutical market for telomerase inhibitors is projected to grow as oncology therapeutics seek precision and targeted options.

Segment	Market Size (USD billions)	Growth Rate (CAGR)	Key Countries
Myelofibrosis treatments	0.7 (2022 estimate)	8% (2022-2028)	US, EU, Japan
MDS therapies	1.2 (2022 estimate)	7.5% (2022-2028)	US, EU, Japan
Telomerase inhibitor market (global)	1.5 (2022)	8.2% (2022-2028)	Global

Source: Reports from MarketsandMarkets, GlobalData (2022)

Imetelstat's potential adheres to the broader telomerase inhibitor market, influenced by unmet needs in hematologic malignancies and emerging biomarker-driven treatment approaches.

Competitive Landscape

Major competitors include other telomerase inhibitors and targeted agents such as:

• Imetelstat’s closest competitors are experimental or off-market drugs, as telomerase inhibition remains a niche.
• Elsewhere, JAK inhibitors like ruxolitinib dominate myelofibrosis markets but face limitations such as resistance.
• The absence of approved telomerase inhibitors offers an initial market advantage if imetelstat gains regulatory approval.

Financial Outlook and Investment Trajectory

Geron Corporation’s current financial position reflects limited revenue, with significant R&D expenses focused on clinical trials. Key financial indicators:

Metric	2022 Data	Comments
R&D Expenses	~$120 million	High investment in clinical trial programs
Revenue	$0	No commercialized product
Cash and Equivalents	~$200 million	Funding for trial continuity and potential commercialization
Market Cap	~$600 million	Reflects speculative nature and clinical progress expectations

Projected timelines assume:

• Phase 3 trial results in 2024 or 2025.
• U.S. NDA submission potentially in late 2025 or early 2026 if clinical results are positive.
• Market entry, if approved, could occur within 2-3 years post-approval.

Regulatory and Policy Environment

• Accelerated approval pathways may be available, given high unmet needs.
• Post-approval, pricing negotiations and reimbursement policies in major markets will significantly impact revenues.
• Orphan drug designation might apply, potentially granting market exclusivity and tax incentives.

Risks and Challenges

• Clinical trial outcomes remain uncertain.
• Regulatory approval may face hurdles if efficacy endpoints are unmet.
• Commercial viability depends on competitive landscape developments and efficacy.

Key Takeaways

• Imetelstat sodium remains in late-stage clinical development without regulatory approval.
• The compound targets a niche but expanding market segment, with a substantial unmet demand in hematologic malignancies.
• Financial investments are significant but poised for potential return contingent on successful trials and approval.
• Market entry is expected around 2025-2026, with long-term commercial success dependent on clinical trial outcomes and market dynamics.

FAQs

1. What is the primary therapeutic target of imetelstat sodium?

   • It inhibits telomerase, an enzyme active in many cancer cells.

2. When could imetelstat sodium reach the market?

   • If trial results are favorable, possible approval by 2025 or 2026.

3. How does imetelstat compare to existing treatments like JAK inhibitors?

   • It targets a different pathway, potentially offering benefits where JAK inhibitors show resistance or limited efficacy.

4. What are the main risks for investors in imetelstat sodium?

   • Clinical trial failure, regulatory setbacks, or commercialization delays.

5. How is the regulatory environment impacting imetelstat’s development?

   • Opportunities exist for expedited review due to the unmet medical needs; risks include rejection or requirement for additional data.

Sources

[1] MarketsandMarkets, "Telomerase Inhibitors Market," 2022.
[2] GlobalData, "Hematology Market Analysis," 2022.
[3] Geron Corporation, Annual Report 2022.
[4] U.S. FDA, "Regulatory Pathways for Oncology Drugs," 2022.